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Abstract Myeloperoxidase, a heme protein secreted by acti-
vated phagocytes, is present and enzymatically active in human
atherosclerotic lesions. In the current studies, we explored the
possibility that reactive nitrogen species generated by myeloper-
oxidase promote lipid peroxidation of low density lipoprotein
(LDL) ^ a modification that may render the lipoprotein
atherogenic. We found that myeloperoxidase, an H2O2-generat-
ing system and nitrite (NO32 ) peroxidized LDL lipids. The
process required NO32 and each component of the enzymatic
system; it was inhibited by catalase, cyanide and ascorbate, a
potent scavenger of aqueous phase radicals. LDL peroxidation
did not require chloride ion, and it was little affected by the
hypochlorous acid scavenger taurine. Collectively, these results
suggest that lipid peroxidation is promoted by a nitrogen dioxide
radical-like species. These observations indicate that myeloper-
oxidase, by virtue of its ability to form reactive nitrogen
intermediates, may promote lipid peroxidation and atherogen-
esis.
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1. Introduction
An elevated level of low density lipoprotein (LDL), the
major carrier of blood cholesterol, is an important risk factor
for atherosclerotic vascular disease [1]. Many lines of evidence
suggest that LDL lipids must be oxidatively modi¢ed to pro-
mote atherogenesis [2^4]. Whereas LDL oxidation has been
widely studied in vitro, the mechanisms that promote it in
vivo remain poorly understood [5]. Early studies demon-
strated that cultured arterial cells oxidize LDL lipids by re-
actions that require iron or copper [6^8]. However, it is un-
certain whether the requisite free (or low molecular weight
chelate) metal ions exist in plasma or tissue [5,9].
We have described a pathway for LDL oxidation that does
not require free metal ions [10^13]. It involves oxidants gen-
erated by myeloperoxidase, an enzyme secreted by phago-
cytes. Myeloperoxidase uses H2O2 to generate cytotoxic oxi-
dants that help defend the host against invading pathogens
[14] ; these oxidants also have the potential to damage host
macromolecules such as LDL [5]. Because the enzyme’s active
site is buried in a hydrophobic cleft [15], it cannot directly
oxidize large molecules. Instead, it relies on low molecular
weight intermediates to convey oxidizing equivalents from
its heme group to its target [10^14].
Another pathway for LDL oxidation that is independent of
free metal ions involves nitric oxide (nitrogen monoxide; NO)
produced by the constitutive nitric oxide synthase of endothe-
lial cells and the inducible nitric oxide synthase of in£amma-
tory cells [16]. When released from the endothelium, NO plays
a critical role in normal physiology by regulating vasomotor
tone. In striking contrast, the larger amounts produced by
in£ammatory cells are cytotoxic [16,17]. Though NO is a rel-
atively stable free radical that fails to oxidize biological tar-
gets, reactive nitrogen species that are derived from it under
pathological conditions may promote LDL oxidation [17,18].
Myeloperoxidase may provide a di¡erent mechanism for
generating reactive nitrogen species. At plasma concentrations
of halide ion, the enzyme uses chloride together with H2O2 to
generate hypochlorous acid (HOCl) [19,20]. This potent oxi-
dant has been proposed to react with nitrite (NO32 ), a major
decomposition product of NO, to yield a reactive intermediate
similar to nitryl chloride, NO2Cl [21^23]:
H2O2  Cl3 H ! HOClH2O
HOClNO32 ! NO2ClHO3
Myeloperoxidase also oxidizes NO32 to a nitrogen dioxide
(NO2)-like radical that nitrates tyrosine and other aromatic
compounds [21^27]:
H2O2 NO32 H ! NO2 HO3 H2O
Polyunsaturated fatty acids exposed to NO2 in vitro under-
go oxidation and nitration [9,28,29]. However, the relative
physiological importance of NO2Cl and NO2 remain poorly
understood.
In the current studies, we show that reactive nitrogen spe-
cies generated by myeloperoxidase promote LDL lipid perox-
idation. The reaction requires NO32 but is independent of
chloride ion, implicating a NO2-like species. Our results there-
fore suggest that myeloperoxidase may provide one pathway
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for promoting LDL lipid peroxidation and nitration in the
artery wall.
2. Materials and methods
Fisher Scienti¢c supplied organic solvents (HPLC grade). Unless
otherwise indicated, all other materials were obtained from Sigma
Chemical Company.
2.1. Myeloperoxidase and LDL preparation
Myeloperoxidase was isolated from HL60 cells by lectin a⁄nity
chromatography and size exclusion chromatography [30]. Myeloper-
oxidase (A430/A280 ratios 0.70) concentration was determined spectro-
photometrically (O430 = 170 mM31 cm31 ; [31]). LDL (d = 1.019^1.063
g/ml) was prepared from pooled plasma (EDTA 4 mM) of healthy
volunteers by discontinuous density gradient ultracentrifugation [32]
and stored under nitrogen at 4‡C in the dark up to 1 week. LDL
protein was determined spectrophotometrically (O280 = 1.05 ml m31
mg31).
2.2. Lipoprotein oxidation
Reactions with myeloperoxidase were carried out at 37‡C in bu¡er
A (50 mM sodium phosphate, 100 WM diethylenetriaminepentaacetic
acid (DTPA), pH 7.4) under conditions where LDL oxidation was a
linear function of enzyme concentration. Bu¡er A was prepared with
deionized glass-distilled water and passed over a Chelex 100 resin
(Bio-Rad) column to remove transition metal ions potentially able
to catalyze oxidation reactions. The reaction mixture contained a ¢nal
concentration of 0.2 mg/ml LDL protein, 50 ng/ml glucose oxidase
(Boehringer Mannheim) and 100 Wg/ml D-glucose.
2.3. Analysis of lipid peroxidation products
LDL oxidation was terminated by lipid extraction using a modi¢ed
Dole procedure [12]. Lipid hydroperoxides were reduced to alcohols
with triphenylphosphine to prevent breakdown during analysis [33].
To release free fatty acids from LDL lipids, the heptane phase was
subjected to gentle base hydrolysis (methanol:5 N potassium hydrox-
ide; 4:1; v:v) for 20 min at 60‡C [33]. Hydrolysis was terminated by
cooling and then acidifying with acetic acid. The acidi¢ed solution
was injected directly into the HPLC system for analysis. Recovery
of 13-hydroxyoctadecadienoic acid (HODE) subjected to this proce-
dure was greater than 85%. Analyses for HODE were performed on a Beckman high performance liquid chromatography (HPLC) system
equipped with a reverse phase column (Ultrasphere; 250 mmU4.6
mm; particle size 5 Wm; Beckman). Oxidized lipids were detected by
monitoring absorbance at 234 nm [3,23]. HODEs were separated us-
ing a solvent system of methanol:water:acetic acid (85:15:0.1; v:v:v)
and a £ow rate of 1 ml/min [12,33]. Authentic 13-HODE was pre-
pared from linoleic acid (Nu Chek Prep Inc.) with soybean lipoxyge-
nase [34] and reduced with triphenylphosphine prior to analysis. Peaks
I and II (Fig. 1) were isolated by HPLC and subjected to positive ion
electrospray ionization-mass spectrometry as described [37].
3. Results
3.1. Myeloperoxidase stimulates lipid peroxidation by a
pathway that requires H2O2 and nitrite
To explore the potential role of myeloperoxidase-derived
oxidants in lipid peroxidation, we exposed LDL to myeloper-
oxidase and a peroxide-generating system in chloride-free so-
dium phosphate bu¡er (pH 7.4). To mimic more closely the
cellular production of oxidant, glucose oxidase was used to
continuously produce H2O2. In the absence of NO32 , we de-
tected only low levels of lipid peroxidation products, moni-
tored by reverse phase HPLC analysis as the appearance of
HODEs (Fig. 1). Adding NO32 to the bu¡er markedly in-
creased lipid peroxidation of LDL. The extent depended on
the concentration of NO32 (Fig. 2A). Little peroxidation was
apparent at [NO32 ]6 10 WM. At higher concentrations of
NO32 , lipid peroxidation rapidly increased and was maximal
at 100 WM.
Fig. 1. Reverse phase HPLC analysis of LDL exposed to the myelo-
peroxidase-H2O2-NO32 system. The complete system consisted of 0.2
mg/ml LDL protein, 40 nM myeloperoxidase, 100 Wg/ml D-glucose,
50 ng/ml glucose oxidase in bu¡er A (50 mM sodium phosphate
bu¡er, 100 WM DTPA, pH 7.4). Where indicated, NO32 was in-
cluded in the reaction mixture. Reactions were initiated by addition
of glucose oxidase. After a 90 min incubation at 37‡C, the reaction
mixture was subjected to lipid extraction, reduction, hydrolysis, and
HPLC analysis. Authentic 13-HODE co-migrated with peak I. Elec-
trospray ionization-mass spectrometric analysis demonstrated that
hydroxylated C18 fatty acids were present in both peak I and peak
II, indicating that these materials are likely to represent isomers of
HODE.
Fig. 2. In£uence of NO32 (A) and progress curve (B) of LDL oxida-
tion by the myeloperoxidase-H2O2 system. LDL was oxidized by
the myeloperoxidase-H2O2 system containing (A) the indicated con-
centration of NO32 or (B) 100 WM NO
3
2 . Where indicated, catalase
was present at 300 nM (a). After (A) a 90 min incubation or (B) at
the indicated time, the reaction mixture was subjected to HPLC
analysis. Results represent (A) mean þ S.E.M. of two independent
experiments with triplicate determinations (similar results were ob-
served in ¢ve independent experiments) and (B) mean þ S.E.M. of
four independent experiments.
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Lipid peroxidation by the myeloperoxidase-H2O2-NO32 sys-
tem exhibited a lag phase, then increased and gradually
slowed (Fig. 2B). All components of the reaction mixture
were required for oxidation (data not shown). Lipid peroxi-
dation was inhibited by the peroxide scavenger catalase (300
nM) and the heme poison cyanide (10 mM), implicating H2O2
and myeloperoxidase in the reaction.
3.2. Inhibition of LDL lipid peroxidation by antioxidants
Probucol and vitamin E are hydrophobic antioxidants that
block chain-propagating radical reactions in the lipid phase
[3,35,36]. In contrast, ascorbic acid prevents the initiation of
lipid peroxidation by scavenging radicals in the aqueous phase
[9,37]. It can also interrupt the propagation phase of lipid
peroxidation by converting oxidized vitamin E back to its
active form [3,36,37]. When LDL was exposed to reactive
nitrogen species generated by the myeloperoxidase-H2O2-
NO32 system, we found that 50 WM ascorbate ^ a well-known
scavenger of NO2 ^ almost completely blocked lipid peroxi-
dation, whereas the same concentration of vitamin E or pro-
bucol was less e¡ective (40% and 60% inhibition, respectively).
Mannitol, a hydroxyl radical scavenger, failed to a¡ect lipid
peroxidation by myeloperoxidase.
3.3. The myeloperoxidase-H2O2-NO32 system stimulates LDL
lipid peroxidation in the presence of the HOCl scavenger
taurine
The major substrate for myeloperoxidase is thought to be
chloride ion [14,19,20]. Recent studies suggest that the enzyme
mediates certain nitration and chlorination reactions via an
NO2Cl-like species derived from HOCl and NO32 [22,23,25].
However, there was no detectable increase in lipid peroxida-
tion when LDL was incubated for 30 min at 37‡C with 100
WM NO32 and 100 WM HOCl. HOCl or NO
3
2 alone also failed
to promote peroxidation.
To further investigate the potential role of NO2Cl in medi-
ating LDL lipid peroxidation, we determined the e¡ect of
chloride and taurine on lipid peroxidation by the myeloper-
oxidase-H2O2-NO32 system. LDL oxidation by myeloperoxi-
dase, H2O2 and NO32 was increased V20% by plasma con-
centrations (100 mM) of chloride (Fig. 3). This increase might
re£ect non-speci¢c ionic e¡ects or generation of HOCl. To
distinguish between these possibilities, we determined whether
lipid peroxidation was inhibited by taurine, a potent scavenger
of HOCl [38]. Taurine (Fig. 3) at up to 1000 WM (10 times the
concentration of NO32 ) failed to a¡ect LDL lipid peroxidation
induced by the complete myeloperoxidase-H2O2-NO32 system
(with or without chloride ion). Collectively, these observations
indicate that HOCl generated by myeloperoxidase is unlikely
to promote LDL lipid peroxidation.
4. Discussion
Our observations indicate that myeloperoxidase and H2O2
convert NO32 into reactive nitrogen species that promote the
peroxidation of LDL lipid. In contrast to generally studied
reactions [2^8], this mechanism for LDL oxidation is inde-
pendent of free metal ions.
Previous studies have suggested that myeloperoxidase can
generate reactive nitrogen intermediates from NO32 by two
distinct pathways [21^27]. One involves the one-electron oxi-
dation of NO32 to NO

2 by compound I, a complex of myelo-
peroxidase and H2O2. This pathway should not require chlor-
ide ion. The other involves the initial generation of HOCl by
compound I, which subsequently reacts with NO32 to yield
NO2Cl, a nitrating and chlorinating intermediate [22,23,25].
This pathway should be inhibited by compounds that react
with HOCl. We found that myeloperoxidase’s ability to ini-
tiate the peroxidation of LDL lipid did not require chloride
ion. Moreover, LDL lipids were not peroxidized by NO32 and
reagent HOCl, and lipid peroxidation by the myeloperoxi-
dase-H2O2-NO32 system was insensitive to taurine, a potent
scavenger of HOCl [38]. The reduction potentials of NO32 and
chloride ion are 30.99 V and 31.36 V [39,40], respectively,
suggesting that myeloperoxidase should preferentially oxidize
NO32 . These observations indicate that the myeloperoxidase
pathway that promotes lipid peroxidation likely involves an
NO2-like species.
Antioxidants might inhibit LDL oxidation by scavenging
myeloperoxidase-derived reactive nitrogen species, thereby
preventing them from initiating lipid peroxidation [9,37],
and by blocking chain-propagating reactions in the lipid
phase [3,35,36]. Ascorbate at a physiologically relevant con-
centration (50 WM) almost completely inhibited lipid peroxi-
dation by the myeloperoxidase-H2O2-NO32 system. In con-
trast, this concentration of vitamin E or probucol only
partially inhibited lipid peroxidation. The di¡erence in po-
tency between lipid and water soluble antioxidants is consis-
tent with the proposed role of NO2 as the oxidizing inter-
mediate, and suggests that ascorbate inhibits LDL lipid
peroxidation by myeloperoxidase through direct scavenging
of reactive nitrogen species.
A key question is whether reactive nitrogen intermediates
produced by myeloperoxidase could oxidize LDL in the artery
wall. In healthy humans, the level of NO32 in plasma is6 5 WM
[41], though concentrations as high as 100 WM are found in
saliva, respiratory £uid and gastric juice as well as in plasma
during in£ammation [42]. The higher concentrations are
similar to those required for LDL lipid peroxidation by
myeloperoxidase in vitro, suggesting that reactive nitrogen
species generated by myeloperoxidase may execute oxidative
reactions at sites of in£ammation in vivo.
Our previous studies have implicated myeloperoxidase in
artery wall damage [10^13,43]. LDL isolated from human
atherosclerotic lesions contains high levels of 3-chlorotyrosine,
Fig. 3. In£uence of chloride ion and taurine on LDL oxidation by
the myeloperoxidase-H2O2-NO32 system. LDL was oxidized by the
myeloperoxidase-H2O2 system containing 100 WM NO32 . Where in-
dicated, 100 mM sodium chloride or taurine was included. After a
90 min incubation at 37‡C, the reaction mixture was subjected to
HPLC analysis. Results represent the mean þ S.E.M. of four inde-
pendent experiments.
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a speci¢c marker of protein oxidation by myeloperoxidase-
generated HOCl [43], indicating that the enzyme chlorinates
lipoproteins in the artery wall. Moreover, human neutrophils
employ the myeloperoxidase system to generate 3-nitrotyro-
sine and 3-chlorotyrosine in vitro [25,43], and LDL isolated
from human atherosclerotic lesions contains markedly ele-
vated levels of 3-nitrotyrosine [44]. Collectively, these obser-
vations raise the possibility that myeloperoxidase both nitrates
and chlorinates host tissues in vivo. Myeloperoxidase pro-
motes peroxidation of LDL lipids at pathophysiological levels
of NO32 . The enzyme may therefore promote atherogenesis by
virtue of its ability to form reactive intermediates, including
NO2, counteracting the well-established anti-atherogenic ef-
fects of low levels of NO.
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